FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies-Reference-Cited by-同舟云学术

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

Published:2002-08 Issue:8 Volume:26 Page:725-730
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

de la Rubia Javier,Regadera Ana I.,Martı́n Guillermo,Cervera José,Sanz Guillermo F.,Martı́nez Jesús A.,Jarque Isidro,Garcı́a Inmaculada,Andreu Rafael,Moscardó Federico,Jiménez Carmen,Mollá Susana,Benlloch Luis,Sanz Miguel A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Varying intensity of postremission therapy in acute myeloid leukemia;Cassileth;Blood,1992

2. Results of randomised trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia;Berman;Blood,1991

3. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia;Wiernick;Blood,1992

4. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a southwest oncology group study;Weick;Blood,1996

5. For the cancer and leukemia group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia;Mayer;N. Engl. J. Med.,1994

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 infection during blinatumomab therapy: Is safety a dilemma?;SAGE Open Medical Case Reports;2023-01

2. Response of the Bone Marrow Stem Cells and the Microenvironment to Stress;Handbook of Stem Cell Therapy;2022

3. Response of the Bone Marrow Stem Cells and the Microenvironment to Stress;Handbook of Stem Cell Therapy;2022

4. Acute myeloid leukemia;Lanzkowsky's Manual of Pediatric Hematology and Oncology;2022

5. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients;Annals of Hematology;2021-04-29